CING: CTx-1301 resubmission nears completion, but nine-month net loss widened to $22.9M
Cingulate says manufacturing work for CTx-1301 FDA requests is largely done, while its nine-month net loss widened to $22.9M, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, manufacturing work needed to address the FDA's chemistry, manufacturing and controls requests for CTx-1301 is substantially complete. The company targets resubmitting its NDA between December 2026 and January 2027.
Cash of $23.2M is expected to fund operations into mid-2027. Meanwhile, the net loss for the first nine months widened to $22.9M.
why it matters
Two factors matter most for investors: the timing of the FDA resubmission and the cash runway. A wider loss while the drug is still awaiting approval makes the need for additional funding a key question.
tags
instruments
sources
- CING: CTx-1301 resubmission nears completion, but 9M net loss widened to $22.9M — TradingView, 13 November 2026 at 22:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗